MA43170A - Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer - Google Patents

Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer

Info

Publication number
MA43170A
MA43170A MA043170A MA43170A MA43170A MA 43170 A MA43170 A MA 43170A MA 043170 A MA043170 A MA 043170A MA 43170 A MA43170 A MA 43170A MA 43170 A MA43170 A MA 43170A
Authority
MA
Morocco
Prior art keywords
inhibitor
bcl
cancer
treatment
combination
Prior art date
Application number
MA043170A
Other languages
English (en)
Inventor
Lina Han
Marina Yurievna Konopleva
Mark Merchant
Deepak Sampath
Original Assignee
Univ Texas
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Genentech Inc filed Critical Univ Texas
Publication of MA43170A publication Critical patent/MA43170A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043170A 2015-11-03 2016-11-03 Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer MA43170A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250231P 2015-11-03 2015-11-03
US201562263082P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
MA43170A true MA43170A (fr) 2018-09-12

Family

ID=57471995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043170A MA43170A (fr) 2015-11-03 2016-11-03 Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer

Country Status (12)

Country Link
US (2) US10959993B2 (fr)
EP (1) EP3370775B1 (fr)
JP (1) JP6724136B2 (fr)
KR (1) KR102124715B1 (fr)
CN (1) CN108601839B (fr)
AU (1) AU2016349279A1 (fr)
BR (1) BR112018008882A8 (fr)
CA (1) CA3001880C (fr)
IL (1) IL258741B (fr)
MA (1) MA43170A (fr)
MX (1) MX379621B (fr)
WO (1) WO2017079399A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104768581A (zh) * 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
US20190328729A1 (en) 2018-04-26 2019-10-31 Emory University Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
TW202023568A (zh) * 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
WO2020077353A2 (fr) 2018-10-12 2020-04-16 The Regents Of The University Of Colorado, A Body Corporate Compositions et méthodes pour réduire les cellules souches cancéreuses
EP4268822A3 (fr) 2018-10-16 2024-01-03 The Johns Hopkins University Compositions permettant de traiter la maladie d'ehlers-danlos
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
WO2020160157A1 (fr) * 2019-01-30 2020-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Détection de complexes hétérodimères de la famille bcl-2 et utilisation associée
US20220136068A1 (en) * 2019-03-06 2022-05-05 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
TWI865521B (zh) * 2019-04-29 2024-12-11 美商免疫遺傳股份有限公司 包含抗ｃｄ１２３免疫結合物之治療組合
EP3976200A4 (fr) * 2019-06-03 2023-07-05 Sanford Burnham Prebys Medical Discovery Institute Utilisations de partenaires létaux synthétiques pour le traitement du cancer
IL294094A (en) * 2019-12-20 2022-08-01 Recurium Ip Holdings Llc conjunctions
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer
CN117257959B (zh) * 2022-12-21 2025-07-29 宁波大学附属人民医院 一种包含Bcl-2抑制剂和STAT抑制剂的药物组合物
CN116270642B (zh) * 2022-12-27 2025-03-21 中国科学技术大学 汉防己甲素在缓解继发性噬血细胞综合症药物中的应用
WO2025043183A1 (fr) * 2023-08-23 2025-02-27 Eigen Therapeutics Inc. Méthodes et compositions de traitement de cancers hématologiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
US20110129456A1 (en) * 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA2811805A1 (fr) 2010-10-29 2012-05-03 Abbvie Inc. Dispersions solides contenant un agent induisant l'apoptose
SG190399A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Methods of treatment using selective bcl-2 inhibitors
CN107266435A (zh) 2010-11-23 2017-10-20 Abbvie 公司 细胞凋亡诱导剂的盐和晶形
MX2014002471A (es) * 2011-08-31 2014-03-27 Novartis Ag Combinaciones sinergicas de los inhibidores de p13k y mek.
SI2884979T1 (sl) 2012-08-17 2019-10-30 Hoffmann La Roche Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba
CN104768581A (zh) 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
US10111897B2 (en) * 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity

Also Published As

Publication number Publication date
EP3370775B1 (fr) 2023-04-19
CN108601839B (zh) 2021-10-26
US20210169865A1 (en) 2021-06-10
US20180303815A1 (en) 2018-10-25
US10959993B2 (en) 2021-03-30
AU2016349279A1 (en) 2018-05-10
BR112018008882A2 (pt) 2018-11-06
CA3001880C (fr) 2021-08-17
JP6724136B2 (ja) 2020-07-15
IL258741A (en) 2018-06-28
KR102124715B1 (ko) 2020-06-18
MX2018005233A (es) 2019-04-29
EP3370775A1 (fr) 2018-09-12
CA3001880A1 (fr) 2017-05-11
MX379621B (es) 2025-03-11
BR112018008882A8 (pt) 2019-02-26
JP2018534298A (ja) 2018-11-22
WO2017079399A1 (fr) 2017-05-11
CN108601839A (zh) 2018-09-28
KR20180054852A (ko) 2018-05-24
HK1259545A1 (en) 2019-11-29
IL258741B (en) 2021-08-31

Similar Documents

Publication Publication Date Title
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3432927A4 (fr) Inhibiteurs trispécifiques pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
EP3383404A4 (fr) Traitement du cancer à l'aide de 2-désoxy-2-fluoro-l-fucose en association avec un inhibiteur de point de contrôle
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3481393A4 (fr) Association d'un antagoniste de pd-1 et d'un inhibiteur du raf pour le traitement du cancer.
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
EP3766497A4 (fr) Médicament pour le traitement de la toux
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP3503887A4 (fr) Combinaisons pour le traitement du cancer